Although this new options generated great therapeutical advances in many cancer contexts (such as the VEGF/VEGFR targeting in kidney cancer8 or in hepatocellular carcinoma, or the anti-BCR/Abl rearrangement for the therapy of chronic monocytic leukemia9) they still often result in a time limited controlled status of the disease, invariably leading to cancer progression in most cases, without considering primary refractories cancer entities, which are not responsive to given targeted therapies since the beginning10. The gene discussed is VEGFA; the disease is cancer.